- Home
- MQ vs VRDN Comparison
MQ vs VRDN Comparison
Compare MQ & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MQ | VRDN |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MQ | VRDN |
|---|---|---|
| Price | $4.34 | $13.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $5.36 | ★ $35.46 |
| AVG Volume (30 Days) | 2.7M | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $624,884,000.00 | $5,706,000.00 |
| Revenue This Year | $16.89 | $13.73 |
| Revenue Next Year | $16.36 | $279.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.25 | N/A |
| 52 Week Low | $3.70 | $11.76 |
| 52 Week High | $7.04 | $34.29 |
Technical Indicators
Market Signals| Indicator | MQ | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 24.57 |
| Support Level | $3.84 | $13.33 |
| Resistance Level | $4.50 | $18.95 |
| Average True Range (ATR) | 0.13 | 0.57 |
| MACD | 0.01 | 0.37 |
| Stochastic Oscillator | 62.38 | 10.66 |
Price Performance
Historical ComparisonAbout MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.